Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Reproduction

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1631108

Impact of Endometrioma Management Strategies on Ovarian Reserve Over the Follow-Up Period, A Prospective Longitudinal Study

Provisionally accepted
Kiper  AslanKiper Aslan1*Işıl  KasapoğluIşıl Kasapoğlu1Bahadir  KosanBahadir Kosan1Tansu  Bahar GurbuzTansu Bahar Gurbuz1Ludovico  MuziiLudovico Muzii2Gurkan  UncuGurkan Uncu1*
  • 1Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye
  • 2La Sapienza University, Roma, Italy

The final, formatted version of the article will be published soon.

Background: The effects of current treatment options for endometrioma on ovarian reserve remain controversial. Recent advancements in surgical techniques may challenge the previously established evidence regarding the detrimental effects of surgery on ovarian reserve. Additionally, whether medical suppression therapy provides a protective effect during this process remains an unanswered question. Furthermore, the impact on ovarian reserve in patients managed expectantly, without active intervention, is unclear. Objective: This study aims to evaluate the effects of endometrioma per se or its treatment modalities on ovarian reserve. Methods: In this prospective study, eighty women diagnosed with endometrioma via ultrasonography and twenty age-matched healthy women as controls were enrolled. The study group was divided into four subgroups, each consisting of twenty patients, based on the treatment modality received: expectant management, oral contraceptive pills (OCP), dienogest, and surgery. All participants underwent baseline ultrasonographic evaluations and blood sampling to determine serum anti-Müllerian hormone (AMH) levels at the time of enrollment. Follow-up assessments, including repeat ultrasonography and AMH measurements, were conducted six months after the initial evaluation. Results: The median six-month decline in serum AMH levels was 19% in the expectant management group, 26% in the OCP group, 21% in the dienogest group, 38% in the surgery group, and 8% in the healthy controls. Thus, statistically significant differences in AMH decline were observed between the OCP group and healthy controls (p=0.034), and between the surgery group and healthy controls (p=0.001). Conclusion: Despite advances in surgical techniques and precautions, surgical excision of endometriomas continues to pose a risk to ovarian reserve. Treatment with both dienogest and OCP is associated with a decrease in serum AMH levels, although the decline appears less significant with dienogest. Patients managed expectantly also showed a progressive decline in ovarian reserve compared to healthy controls.

Keywords: Endometrioma, Anti-Mullerian Hormone, Endometriosis, ovarian reserve, Oral contraceptives (OCPs)

Received: 19 May 2025; Accepted: 27 Aug 2025.

Copyright: © 2025 Aslan, Kasapoğlu, Kosan, Gurbuz, Muzii and Uncu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Kiper Aslan, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye
Gurkan Uncu, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.